HEPATIC IMPAIRMENT

This completed Phase 1 study looked at how the drug tirabrutinib is processed in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Forty participants took a single oral dose, and researchers measured drug levels and safety. The goal was to und…

This study looked at how the drug ITF2357 is handled by the body in people with chronic liver disease compared to healthy volunteers. 24 adults received a single 50 mg dose by mouth. The goal was to measure drug levels and check safety, not to treat the liver condition.

This study looked at how a single dose of MY008211A tablets moves through the body in people with different levels of liver function. 24 adults (some with liver problems, some without) took part. The goal was to understand safety and how the liver affects drug levels, not to trea…

This completed Phase 1 study looked at how the experimental cholesterol-lowering drug enlicitide is processed in the body of people with mild or moderate liver impairment compared to healthy volunteers. Twenty participants received a single oral dose, and researchers measured dru…

This study looked at how the drug LY3502970 enters the bloodstream and leaves the body in people with different levels of liver function. 29 participants, including healthy volunteers and those with mild to severe liver impairment, took a single dose. The goal was to understand d…

This study looked at how the drug MCI-186 (also called edaravone) behaves in people with mild or moderate liver impairment compared to those with healthy livers. Twenty-two participants received a single dose of the drug. The goal was to see if liver problems affect how the drug …

This study looked at how a single dose of the drug AZD2693 moves through the body in people with liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood to understand safety and processing differences. A total of 35 adults took part. The goa…

This study looked at how the body processes a drug called ESK001 in people with different levels of liver function. Researchers gave a single dose to 32 adults, including healthy volunteers and those with mild, moderate, or severe liver impairment. The goal was to measure drug le…

This completed Phase 1 study looked at how the drug seladelpar (Livdelzi) is processed in 24 people with primary biliary cholangitis (PBC) who also have liver impairment. Researchers measured drug levels in the blood and urine to see how the liver condition affects the drug. The …

This completed Phase 1 study looked at how moderate and severe liver impairment changes the way the body handles a single dose of palovarotene, compared to healthy people. Thirty-one participants were split into three groups based on liver function and received up to 10 mg of the…

This early-stage study tested a single 4 mg dose of the drug elpipodect (MK-8189) in 14 people—some with mild or moderate liver problems and some healthy. Researchers measured how much drug stayed in the blood and for how long. The goal was to see if liver impairment changes drug…

This early-phase study looked at how the body breaks down nalbuphine extended-release tablets in people with mild, moderate, or severe liver impairment compared to healthy volunteers. It also explored whether the drug could relieve itching in those with liver problems. The study …

This study looked at how the body handles a single shot of fazirsiran in 34 people with mild, moderate, or severe liver problems, compared to those with healthy livers. Participants were followed for 6 months after the injection. The goal was to measure drug levels and check for …

This study looked at how the body processes a single dose of the drug AMG 133 in people with different levels of liver impairment compared to those with healthy livers. Thirty-six adults took part, and researchers measured drug levels in the blood and checked for side effects. Th…

This study looked at how the drug BPN14770 is handled by the body in people with mild, moderate, or severe liver impairment compared to healthy people. A total of 32 adults took a single dose of the drug. Researchers measured drug levels in the blood and checked for side effects.…

This completed Phase 1 study looked at how the drug MK-8527 moves through the body in people with mild or moderate liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood over time to understand how liver function affects the drug. The study…

This study looked at how the experimental prostate cancer drug opevesostat moves through the body in men with moderate liver impairment compared to healthy men. Sixteen male participants received a single dose, and researchers measured drug levels over time. The goal was to under…

This study tested a single injection of a new drug (NNC0194-0499) for non-alcoholic fatty liver disease in 33 people with various degrees of liver impairment and healthy volunteers. The goal was to see how the liver processes the drug and whether it is safe. Results will help det…

This completed Phase 1 study looked at how the drug HRS-5965 behaves in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-four adults took a single 50 mg dose of the drug. The goal was to measure drug levels in the blood and check …

This completed Phase 1 study looked at how the drug bulevirtide (Hepcludex) behaves in the body of people with normal liver function and those with liver impairment. Researchers measured drug levels in the blood and how quickly it is cleared. The study involved 74 participants an…

This completed Phase 1 study looked at how the drug golcadomide is processed in the body of people with moderate or severe liver impairment compared to healthy volunteers. 29 adults received a single dose, and researchers measured drug levels and safety. The goal is to understand…

This study looked at how camlipixant, an experimental drug for chronic cough, behaves in people with liver problems compared to healthy volunteers. 32 adults aged 18-75 took part to see if liver impairment changes drug levels or safety. The goal is to help doctors decide the righ…

This study looked at how a single dose of the antifungal drug fosmanogepix is processed in the bodies of 28 adults with varying degrees of liver impairment. Participants took one pill by mouth, and researchers measured drug levels in the blood over time. The goal was to see if li…

This study tests how the experimental drug cagrilintide, being developed for weight management, is processed by the body in people with different levels of liver function. It involves 32 participants, including those with liver impairment and healthy volunteers. The goal is to se…

This study looked at how the drug divarasib is processed in the bodies of 31 people with different levels of liver function, from healthy to severely impaired. Participants received a single dose, and researchers measured drug levels in the blood over time. The goal was to unders…

This study looks at how the drug BI 1015550 is absorbed and processed in the blood of people with mild or moderate liver problems compared to those with healthy livers. About 28 adults took a single dose and had blood samples taken over several days. The goal is to understand if …

This completed Phase 1 study tested a single 50 mg dose of the drug KP-001 in 24 adults, some with healthy livers and others with different levels of liver impairment. The goal was to see how liver function affects the drug's levels and safety in the body. Results could help guid…

This study looked at how different levels of liver impairment affect the way the body processes a single dose of the drug evobrutinib. Twenty-four participants with either normal liver function or mild to moderate liver impairment took one dose of the drug. Researchers measured d…

This study looked at how the drug efinopegdutide behaves in people with moderate to severe liver damage compared to healthy people. A total of 22 adults took a single dose, and researchers measured drug levels and safety. The goal was to understand dosing needs for patients with …

This study looked at how the drug olpasiran is processed by the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. A total of 25 adults took a single dose of the drug. The goal was to understand safety and how the liver affects dru…

This completed Phase 1 study looked at how a single dose of the drug AZD5004 moves through the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. The goal was to measure drug levels and check safety. 33 adults aged 18-80 took part. The …

This study looked at how a single dose of the drug repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults took part to help understand if liver problems change drug levels. The results will guide dosing for pa…

This study looked at how the drug AZD2389 behaves in people with liver impairment compared to healthy volunteers. 35 adults took a single dose, and researchers measured drug levels in the blood to check safety and processing. The goal is to understand if liver problems change how…

This completed Phase 1 study looked at how a single 0.5 mg dose of the drug cenerimod is processed in 24 people — some with mild or moderate liver impairment and some healthy. The goal was to see if liver problems change drug levels or safety. Participants were monitored for side…

This completed Phase 1 study looked at how olomorasib, an oral drug, enters the bloodstream and leaves the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. 46 participants received a single dose. The goal is to understand if liver fun…